Knowledge of genomic testing among early-stage breast cancer patients

Psycho-Oncology

Volumn 20, Issue 1, 2011, Pages 28-35

  Richman, Alice R ^a   Tzeng, Janice P ^a   Carey, Lisa A ^b,c   Retèl, Valesca P ^d   Brewer, Noel T ^a,c  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

adjuvant therapy; decision making; early stage breast cancer; genomic testing; recurrence risk

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER STAGING; COMORBIDITY; CROSS-SECTIONAL STUDY; EARLY CANCER; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; KNOWLEDGE; LYMPH NODE; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; MENOPAUSE; METASTASIS; PATIENT DECISION MAKING; PATIENT EDUCATION; QUESTIONNAIRE; RATING SCALE; READING; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CROSS-SECTIONAL STUDIES; DECISION MAKING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECURRENCE; RISK;

EID: 78650674744     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1699     Document Type: Article

References (32)

1. Morris SR, Carey LA,. Gene expression profiling in breast cancer. Curr Opin Oncol 2007; 19: 547-551.
2. Henry LR, Stojadinovic A, Swain SM, et al,. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009; 99: 319-323.
3. Asad J, Jacobson AF, Estabrook A, et al,. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008; 196: 527-529.
4. Oakman C, Bessi S, Zafarana E, et al,. New diagnostics and biological predictors of outcomes in early breast cancer. Breast Cancer Res 2009; 11: 205-216.
5. Paik S, Shak S, Tang G, et al,. A multigene assay to predict recurrence of tamoxifen-treated, node-negative brest cancer. N Engl J Med 2004; 351: 2817-2826.
6. Wolf I, Baruch NB, Shapira-Frommer R, et al,. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 2008; 112: 731-736.
7. Paik S, Shak S, Tang G, et al,. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 98: 1183-1192.
8. Goldstein LJ, Gray R, Badve S, et al,. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26: 4063-4071.
9. Albain K, Barlow W, Shak S, et al,. Prognosticand predictive value of the 21-gene recurrence score assay in postmenopausal, nodepositive, ER-positive breast cancer (S8814,INT0100). Presented at the 30th Annual San Antonio Breast Cancer Symposium; 13-16 December 2007, San Antonio, Texas. Abstract 10.
10. Degner LF, Kristjanson LJ, Bowman D, et al,. Information needs and decisional preferences in women with breast cancer. JAMA 1997; 277: 1485-1492.
11. Keating KL, Guadagnoli E, Landrum MB, et al,. Treatment decision making in early stage breast cancer: should surgeons match patients' desired level of involvement? J Clin Oncol 2002; 20: 1473-1479.
12. Thomas R, Godward S, Makris A, et al,. Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised crossover study comparing letrozole with anatrozole. Clin Oncol (R Coll Radiol) 2004; 16: 485-491.
13. Fallowfield L, Atkins L, Catt S, et al,. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006; 17: 205-210.
14. Partridge AH, Wang PS, Winer EP, et al,. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21: 602-606.
15. Atkins L, Fallowfield L,. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006; 42: 2271-2276.
16. Lillie SE, Brewer NT, O'Neill SC, et al,. Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy. Cancer Epidemiol Biomarkers Prev 2007; 16: 249-255.
17. Wengström Y, Aapro M, Leto di Priolo S, et al,. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 2007; 16: 462-468.
18. Virnig BA, Baxter NN, Habermann EB, et al,. A matter of race: early-versus late-stage cancer diagnosis. Health Aff 2009; 28: 160-168.
19. Albano JD, Ward E, Jemal A, et al,. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 2007; 99: 1384-1394.
20. Schwartz LM, Woloshin S, Black WC, et al,. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997; 127: 966-973.
21. Charlson ME, Pompei P, Ales KL, et al,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
22. Degner LF, Sloan JA, Venkatesh P,. The control preferences scale. Can J Nurs Res 1997; 29: 21-43.
23. Bruera E, Sweeney C, Calder K, et al,. Patient preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol 2001; 19: 2883-2885.
24. Grunfeld EA, Maher EJ, Browne S, et al,. Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. J Clin Oncol 2006; 24: 1090-1098.
25. O'Neill SC, Brewer NT, Lillie SE, et al,. Women's interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol 2007; 25: 4628-4634.
26. Harris KA,. The informational needs of patients with cancer and their families. Cancer Pract 1998; 6: 39-47.
27. Yancik R, Wesley MN, Ries LAG, et al,. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-892.
28. Newschaffer CJ, Penberthy L, Desch CE, et al,. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996; 156: 85-90.
29. Bergman L, Dekker G, van Kerhoff EH, et al,. Influence of age and comorbidity on treatment choice and survival in elderly patients with breast cancer. Breast Cancer Res Treat 1991; 18: 189-198.
30. Piccirillo JF, Feinstein AR,. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996; 77: 834-842.
31. Satariano WA, Silliman RA,. Comorbidity: implications for research and practice in geriatric oncology. Crit Rev Oncol Hemat 2003; 48: 239-248.
32. Morris NS, MacLean CD, Chew LS, et al,. The single item literacy screener: evaluation of a brief instrument to identify limited reading ability. BMC Fam Pract 2006; 7: 21.